Clinical Trial

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-14.
Trial Details
NCT Number NCT06137300
Lead Sponsor Yi Yang
Conditions Acute Ischemic Stroke
Enrollment 986 participants
Start Date 2024-03-15
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-28